A recent report published by Infinium Global Research on the migraine drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional migraine drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional migraine drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of global migraine drugs market. According to the report, the global migraine drugs market is projected to grow at a CAGR of 8.38% over the forecast period of 2020-2026.

Market Insight

Migraine is a clinical condition of neurology which can cause numerous symptoms. It is marked often by severe and devastating headaches. Symptoms can consist of nausea, vomiting, difficulty speaking, numbness or tingling, and several others. Furthermore, the diagnosis of migraine headaches is evaluated from clinical history and reported symptoms. Moreover, females are more prone to experience migraines than men. Genetic background is one of the most general sign factors for migraines. Symptoms of migraines will start one to two days before the headache itself and this is categorized as a stage of the prodrome. In addition, migraine pain frequently impacts the area of the forehead. It's usually on one side of the head, but on both sides, it may arise. Migraines are more common in women, with 17.0% of women reporting an attack compared to 6.0% men, each year. The global Migraine Drugs market was sized near USD 4.80 billion in 2019. The Migraine Drugs market is expected to grow at a CAGR of 8.38% during the forecast period.

The growing awareness regarding migraine and numerous options available for its treatment are the major factors responsible for the growth of the global migraine drugs market in the near future. A number of organizations comprising the American Headache and Migraine Association are taking efforts to spread awareness about migraine and therefore coming up with programs and offering support to patients so as to spread awareness regarding the disease and further disorders associated with a headache. However, Migraine preventive medicines such as beta-blockers, calcium channel blockers, and antidepressants are also associated with adverse side effects such as fatigue, depression, dizziness, lowered blood pressure, weight gain, constipation, sedation, decreased libido among others. Many patients are unable to tolerate these side effects and discontinue their treatments. This has led to a decline in the acceptability of drugs used for the treatment of migraines. Moreover, owing to the growing number of migraine incidences and an increasing number of unmet needs in the global migraine drugs market, a number of vendors are planning to invest in the migraine drugs R&D. This, in turn, is estimated to propel the global migraine drugs market growth over the projection period.

Among the regions, North America dominates the global migraine drugs market followed by Europe. Migraine is the third most prevalent and the sixth most disabling illness across the globe, affecting more than 37 million in the United States and over one billion people worldwide. The increasing prevalence of migraines and the increasing adoption of novel therapeutics are the major demand driving factors in the North American region. Furthermore, in the European region, the increasing geriatric population and better reimbursement policies are upsurging the demand for migraine drugs. However, the Asia Pacific region is expected to grow at a rapid rate over the forecast period owing to the presence of emerging opportunities, improving healthcare infrastructure, and increasing patient awareness. In addition, the low-cost production of drugs across the region is one of the significant growth drivers for this market.

Segment Covered

The report on the global migraine drugs market covers segments such as therapeutic class, and treatment type. On the basis of therapeutic class, the sub-markets include ergot, triptans, and others. On the basis of treatment type, the sub-markets include abortive, and abortive preventive.

Companies Profiled:

The report provides profiles of the companies in the market such as GlaxoSmithKline PLC, Amgen Inc., ALLERGAN PLC, ELI LILY & Company, Merck KGaA, Amneal Pharmaceuticals Inc., H. Lundbeck A/S, Neurelis Inc., Pfizer Inc., and Zogenix, Inc..

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of migraine drugs market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.